HC Wainwright Issues Negative Outlook for ABEO Earnings

Key Points

• HC Wainwright lowered its Q4 2027 EPS forecast for Abeona Therapeutics to a loss of $0.01 per share from a projected profit of $0.01, while maintaining a Buy rating and $20 price target.
• Abeona’s latest results missed expectations, with a quarterly loss of $0.35 per share versus the $0.23 consensus estimate and revenue of $11.38 million versus $12.24 million expected.
• Analyst sentiment is mixed: the stock carries an average Hold rating and $19.33 target price, while shares recently opened at $6.06. Institutional investors own 80.56% of the company, and insiders sold shares primarily to cover tax obligations.

Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) - Research analysts at HC Wainwright dropped their Q4 2027 earnings per share (EPS) estimates for Abeona Therapeutics in a research report issued on Monday, August 24th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will earn ($0.01) per share for the quarter, down from their previous forecast of $0.01. HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. The consensus estimate for Abeona Therapeutics' current full-year earnings is ($0.92) per share.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.12). The firm had revenue of $11.38 million for the quarter, compared to the consensus estimate of $12.24 million.

Several other research analysts have also recently weighed in on the stock. Oppenheimer reaffirmed an "outperform" rating and issued a $21.00 price target (down from $22.00) on shares of Abeona Therapeutics in a report on Friday, August 14th. Wall Street Zen raised Abeona Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 1st. Finally, Weiss Ratings cut Abeona Therapeutics from a "sell (d+)" rating to a "sell (d)" rating in a research report on Monday, August 17th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $19.33.

Abeona Therapeutics Stock Performance

NASDAQ ABEO opened at $6.06 on Tuesday. The company's 50 day simple moving average is $6.38 and its two-hundred day simple moving average is $5.61. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.63 and a quick ratio of 6.40. Abeona Therapeutics has a 1 year low of $4.00 and a 1 year high of $7.65. The stock has a market capitalization of $346.51 million, a PE ratio of -5.56 and a beta of 1.35.

Institutional Investors Weigh In On Abeona Therapeutics

A number of large investors have recently made changes to their positions in ABEO. Legal & General Group Plc purchased a new position in Abeona Therapeutics during the 2nd quarter valued at about $27,000. Royal Bank of Canada boosted its position in shares of Abeona Therapeutics by 49.6% during the first quarter. Royal Bank of Canada now owns 6,500 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 2,155 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Abeona Therapeutics in the third quarter worth approximately $37,000. Truvestments Capital LLC grew its position in Abeona Therapeutics by 191.4% in the 4th quarter. Truvestments Capital LLC now owns 10,307 shares of the biopharmaceutical company's stock worth $54,000 after purchasing an additional 6,770 shares during the period. Finally, Sherbrooke Park Advisers LLC purchased a new position in shares of Abeona Therapeutics in the 3rd quarter worth $64,000. 80.56% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Abeona Therapeutics

In other Abeona Therapeutics news, insider Madhav Vasanthavada sold 12,606 shares of the company's stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $6.96, for a total value of $87,737.76. Following the completion of the sale, the insider owned 290,623 shares of the company's stock, valued at $2,022,736.08. This represents a 4.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Vishwas Seshadri sold 67,971 shares of the company's stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $6.96, for a total transaction of $473,078.16. Following the completion of the sale, the chief executive officer directly owned 1,306,108 shares of the company's stock, valued at $9,090,511.68. This trade represents a 4.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 274,578 shares of company stock valued at $1,674,433 over the last quarter. Company insiders own 7.10% of the company's stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company's research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company's lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source